drugset / Trial / NCT00858156
BG9928 in Subjects With Hepatic Impairment
Non-randomizedParallel-groupOpen-label
Summary
The primary objective of the study is to evaluate the effect of hepatic function on the pharmacokinetics of a single oral dose of BG9928 in subjects with mild and moderate hepatic impairment and in subjects with normal hepatic function.
Timeline
- Start
- 2009-04
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tonapofylline | Small molecule | 75 mg | Oral |
Indications
No indication recorded.